Volume 23, Issue 6 pp. 906-910
Clinical commentary

Exacerbation of eyelid myoclonia in patients with epilepsy and eyelid myoclonia receiving cannabidiol

Ifrah Zawar

Ifrah Zawar

Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Linfa Franic

Linfa Franic

Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Prakash Kotagal

Prakash Kotagal

Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Elia Pestana Knight

Corresponding Author

Elia Pestana Knight

Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence: Elia Pestana Knight Epilepsy Center Cleveland Clinic 9500 Euclid Avenue, S-5 Cleveland, OH 44195, USA <[email protected]>Search for more papers by this author
First published: 07 January 2022
Citations: 4

Abstract

Epilepsy with eyelid myoclonia or Jeavons Syndrome (JS) is a childhood genetic generalized epilepsy. Its clinical features include eyelid myoclonia (hallmark) with or without brief absences, eyelid closure-induced seizures and/or electroencephalographic (EEG) paroxysms (generalized polyspikes and/or generalized spike-wave activity at 3-6 Hz, elicited by closure of eyelid) and photosensitivity. Broad-spectrum anti-seizure medications are often utilized for the management of JS patients. A wide variety of medications may be utilized especially in refractory cases. Efficacy or safety of cannabidiol (CBD) for JS has not been studied. We describe two cases of exacerbation of eyelid myoclonia in JS which correlated with CBD use and resolved after CBD discontinuation. These cases highlight that caution should be practiced when using CBD for JS as it can potentially worsen eyelid myoclonia.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.